[go: up one dir, main page]

JP2714413B2 - 皮膚浸透が増強された医薬組成物 - Google Patents

皮膚浸透が増強された医薬組成物

Info

Publication number
JP2714413B2
JP2714413B2 JP63501529A JP50152988A JP2714413B2 JP 2714413 B2 JP2714413 B2 JP 2714413B2 JP 63501529 A JP63501529 A JP 63501529A JP 50152988 A JP50152988 A JP 50152988A JP 2714413 B2 JP2714413 B2 JP 2714413B2
Authority
JP
Japan
Prior art keywords
lecithin
pharmaceutical composition
skin penetration
enhanced skin
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP63501529A
Other languages
English (en)
Other versions
JPH02502994A (ja
Inventor
フオージ，マーデイ
イーヤー，ウーマ・アール
マージヤー，マジド
Original Assignee
ワーナー‐ランバート・コンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21895652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2714413(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ワーナー‐ランバート・コンパニー filed Critical ワーナー‐ランバート・コンパニー
Publication of JPH02502994A publication Critical patent/JPH02502994A/ja
Application granted granted Critical
Publication of JP2714413B2 publication Critical patent/JP2714413B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】 発明の背景 商業上用いられるレシチンは油種子（例えば大豆およ
びナタネ種子）からおよび卵黄から主に得られる脂肪中
に存在する一群の物質に与えられた名称である。商業上
のレシチンは食品および医薬製品、例えばクリーム、バ
ルム剤、または軟膏に使用される天然の乳化剤である。
レシチンはまた噴射剤における分散物または懸濁物中
にもその使用が記載されている。例えば、気管支拡張剤
はレシチンを含有する噴射剤中にて吸入手段により投与
されうる。
今、レシチンが皮膚を通しておよびその他の生物学的
膜例えば腸、頬、直腸、および鼻からの薬物の浸透を高
める事が見出された。それゆえ本発明の目的は医薬組成
物中にレシチンを使用することによる経皮的または経粘
膜的な薬物の投与法にある。
発明の要約 従って、本発明は活性成分および有効量のレシチンを
含有する医薬組成物を薬物を必要とする宿主の皮膚また
は膜に投与することからなる皮膚およびその他の生物学
的膜を通した薬物の浸透を高める方法に関する。
本発明のもう一つの観点は活性成分および有効量のレ
シチンを含有する、経皮的または経粘膜的な投与に適合
する医薬組成物にある。
好ましい態様の記載 経皮用医薬組成物は経口投与の不確実さおよび注射に
よる投与の不便さを回避する手段として用いられてい
る。
本発明のための活性成分は任意の治療上活性な薬物の
有効量である。
好ましい薬物は種々の治療上の用途に適用できるもの
であり、例えば抗高血圧剤、鎮痛剤、鎮咳剤、抗ヒスタ
ミン剤、気管支拡張剤、認識活性化剤、その他である。
それゆえ、レシチン組成物はプロカテロール（procater
ol）、デキストロメトルフアン（dextromethorphan）、
オキシモルフオン（oxymorphone）、ジフエンヒドラミ
ン、その他のような薬物中に使用できることが予想され
る。
本発明で用いられるレシチンは市販のレシチンまたは
大豆レシチン、例えばエピクロン（EpikuronTM）135Fお
よびキヤプシチン（CapcithinTM）50−ＲのようなLucas
Meyer,Inc.社の市販の大豆レシチンである。経皮的調
製物に使用されるレシチンの量は必要な活性成分の量お
よび他の付形剤の使用に如何に応じて変動できる。浸透
増強に有効であることが判明したレシチンの有用な範囲
は組成物の約２〜約40重量％である。好ましくは約５〜
約10％である。
本発明の組成物は製剤上受容されうる付形剤をも含有
しうる。それらには例えばテトラグリコール（TG）、ア
ルコール類、グリコール類、脂肪酸類、トリアセチン、
シリコン液、等がある。
表の形態をした以下の実施例により本発明を説明す
る。それにより市販の大豆レシチンの使用がマウスの皮
膚を通した種々の薬物の浸透を高めることが判る。
フロントページの続き (72)発明者 マージヤー，マジド アメリカ合衆国ニユージヤージー州 07857．ネツトコング．コクラスドライ ブ82 (56)参考文献 特開 昭62−123132（ＪＰ，Ａ)

Claims (3)

    (57)【特許請求の範囲】
  1. 【請求項１】治療上有効な量の活性成分、有効量の市販
    レシチンおよび１種もしくはそれ以上の製剤上受容され
    うる付形剤を含有する、経皮的または経粘膜的な投与に
    適合する医薬組成物。
  2. 【請求項２】市販レシチンの量が２〜40％であることか
    らなる請求項１記載の組成物。
  3. 【請求項３】活性成分がジフェンヒドラミン、デキスト
    ロメトルファン、オキシモルフォンまたはプロカテロー
    ルである請求項１記載の組成物。
JP63501529A 1987-04-13 1988-03-18 皮膚浸透が増強された医薬組成物 Expired - Lifetime JP2714413B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/037,671 US4783450A (en) 1987-04-13 1987-04-13 Use of commercial lecithin as skin penetration enhancer
US37,671 1987-04-13

Publications (2)

Publication Number Publication Date
JPH02502994A JPH02502994A (ja) 1990-09-20
JP2714413B2 true JP2714413B2 (ja) 1998-02-16

Family

ID=21895652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63501529A Expired - Lifetime JP2714413B2 (ja) 1987-04-13 1988-03-18 皮膚浸透が増強された医薬組成物

Country Status (5)

Country Link
US (1) US4783450A (ja)
EP (1) EP0382716B2 (ja)
JP (1) JP2714413B2 (ja)
DE (1) DE3887156T3 (ja)
WO (1) WO1988007871A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009110205A1 (ja) 2008-03-04 2009-09-11 ナガセケムテックス株式会社 ヒアルロン酸増量剤

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981681A (en) * 1988-08-26 1991-01-01 Vittorio Tosti Lotion mixture and method of treating psoriasis
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5498607A (en) * 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
WO1993011767A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company Transdermal delivery of (e)-1,2,5,6-tetrahydro-1-methyl-3-pyridine-carboxaldehyde-o-methyloxine hcl and related compounds in the treatment of cognitive disorders and for analgesia
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
ATE137959T1 (de) * 1992-02-12 1996-06-15 Janssen Cilag S P A Liposomale piroxycam formulierung
EP0625898B1 (en) * 1992-02-12 1996-05-15 JANSSEN-CILAG S.p.A. Liposomal piroxicam formulations
EP0625899B1 (en) * 1992-02-12 1996-05-29 JANSSEN-CILAG S.p.A. Liposomal itraconazole formulations
TW224048B (ja) * 1992-03-30 1994-05-21 Hoechst Roussel Pharma
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
CA2165802A1 (en) * 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
WO1997002041A1 (en) 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
SE9601528D0 (sv) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5709878A (en) * 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
GB2331924A (en) * 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6011022A (en) * 1998-03-03 2000-01-04 El Khoury; George F. Topical application of muscarinic analgesic drugs such as neostigmine
KR100638150B1 (ko) 1998-12-23 2006-10-26 이데아 악티엔게젤샤프트 생체내에서 국부적인 비침습성 용도로 사용되는 개선된 제제
ATE216223T1 (de) 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
DE10024413A1 (de) * 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
DE60127277T2 (de) * 2000-08-03 2007-11-29 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
AU2002250071B2 (en) 2001-02-13 2008-02-14 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
AU2002316053A1 (en) 2001-05-01 2002-11-11 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2003101357A1 (en) * 2002-05-31 2003-12-11 University Of Mississippi Transmucosal delivery of cannabinoids
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
NZ546106A (en) 2003-10-10 2008-10-31 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20050191338A1 (en) * 2004-01-30 2005-09-01 Lifeng Kang Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
KR20070007299A (ko) 2004-01-30 2007-01-15 코리움 인터네셔널, 인크. 활성제의 전달을 위한 급속 용해 필름
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
JP2007538010A (ja) 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
JP5117846B2 (ja) * 2005-02-25 2013-01-16 久光製薬株式会社 抗炎症剤及び大豆レシチンを含有する外用剤
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
KR20140143461A (ko) 2007-08-06 2014-12-16 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
US20110052738A1 (en) * 2008-01-17 2011-03-03 Gary Dean Bennett Topical pain formulation
SG10201608068SA (en) 2008-04-01 2016-11-29 Antipodean Pharmaceuticals Inc Compositions And Methods For Skin Care
US20090258070A1 (en) 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
DK2712622T3 (en) 2008-05-21 2016-09-12 Ferring Bv Orodispergibel desmopressin to the extension of the initial period of sleep, undisturbed by nocturia.
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US8592386B2 (en) 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
AU2010210620B2 (en) 2009-02-03 2016-02-25 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
DK2704704T3 (en) 2011-05-03 2019-01-14 Dupont Nutrition Biosci Aps PROBIOTIC BACTERIES FOR TOPICAL TREATMENT OF SKIN DISORDERS
WO2013003825A1 (en) 2011-06-29 2013-01-03 Allergan, Inc. Alcaftadine for use in the treatment of urticaria
SG10202011046RA (en) 2012-09-21 2020-12-30 Intensity Therapeutics Inc Method of treating cancer
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
AU2014293141A1 (en) 2013-07-23 2016-02-18 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
CN105579056A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与5-α还原酶抑制剂组合的去氨加压素的方法和组合物
AU2014349150B2 (en) 2013-11-15 2019-11-07 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
US20150182451A1 (en) * 2013-12-27 2015-07-02 The Dial Corporation Cleansing composition for hormone deposition
WO2016025945A1 (en) 2014-08-15 2016-02-18 The Johns Hopkins University Technology Ventures Composite material for tissue restoration
US10286033B2 (en) 2014-11-20 2019-05-14 Serenity Pharmaceuticals, Llc Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
PL3250208T3 (pl) 2015-01-30 2021-04-06 Oncoceutics, Inc. 7-benzylo-4-(4-(trifluorometylo)benzylo)-1,2,6,7,8,9-heksahydroimidazo[1,2-a]pirydo[3,4-e]pirymidyn-5(4h)-on oraz jego sole i ich zastosowanie w terapii
CN107613961B (zh) * 2015-05-19 2021-07-13 美德阿利克斯株式会社 经皮吸收型液体制剂
US20190060516A1 (en) 2015-08-17 2019-02-28 The Johns Hopkins University In situ forming composite material for tissue restoration
LT3408298T (lt) 2016-01-29 2025-03-10 Oncoceutics, Inc. Su g baltymu susieto receptoriaus (gpcr) moduliavimas imipridonais
US20190328770A1 (en) 2016-12-30 2019-10-31 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
EP3790602A1 (en) 2018-05-09 2021-03-17 The Johns Hopkins University Nanofiber-hydrogel composites for cell and tissue delivery
CA3099733A1 (en) 2018-05-09 2019-11-14 The Johns Hopkins University Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration
EP3863622B1 (en) 2018-10-09 2024-07-24 University Of Rochester Treatment of vulvovaginal disorders
US20220000818A1 (en) 2019-01-25 2022-01-06 Nogra Pharma Limited Compositions for use in preventing acne
AU2021376539A1 (en) * 2020-11-06 2023-06-15 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology
WO2024156864A2 (en) 2023-01-27 2024-08-02 Nogra Pharma Limited Fatty acid compounds and methods of use
WO2024173675A1 (en) 2023-02-16 2024-08-22 University Of Rochester Improving glymphatic-lymphatic efflux
WO2024226871A1 (en) 2023-04-27 2024-10-31 Mccord Darlene E Compositions and methods of dissolving biofilm to promote wound healing
WO2025038701A1 (en) 2023-08-15 2025-02-20 Tryglobal Ip, Holdings Llc Composite materials and methods of using the same for wound healing and antimicrobial applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2001334B (en) * 1977-07-19 1982-03-03 Fisons Ltd Pressurised aerosol formulation
FR2478485A1 (fr) * 1980-03-24 1981-09-25 Oreal Compositions cosmetiques ou pharmaceutiques sous forme d'emulsions stables du type huile-dans-l'eau
US4699776A (en) * 1985-06-28 1987-10-13 R. P. Scherer Corporation Suppositories containing analgesics, antipyretics or anti-inflammatory agents
JPS62123132A (ja) * 1985-11-21 1987-06-04 Michio Nakanishi 気管支喘息治療用組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009110205A1 (ja) 2008-03-04 2009-09-11 ナガセケムテックス株式会社 ヒアルロン酸増量剤

Also Published As

Publication number Publication date
EP0382716A1 (en) 1990-08-22
EP0382716B2 (en) 1998-01-28
JPH02502994A (ja) 1990-09-20
EP0382716B1 (en) 1994-01-12
WO1988007871A1 (en) 1988-10-20
US4783450A (en) 1988-11-08
DE3887156T2 (de) 1994-04-28
DE3887156D1 (de) 1994-02-24
DE3887156T3 (de) 1998-04-16

Similar Documents

Publication Publication Date Title
JP2714413B2 (ja) 皮膚浸透が増強された医薬組成物
KR0182811B1 (ko) 근육긴장을 억제하기 위한 활성물질 플루피르틴-함유 약제 및 이의 제조방법
KR100622285B1 (ko) 나노분산액을 사용한 약제학적 최종 제형의 제조 방법, 나노분산액의 예비상 및 나노분산액
EP2373346B1 (en) Ibuprofen for topical administration
KR101710435B1 (ko) 칼라놀라이드, 이의 유도체 및 유사체에 대한 약학 조성물 및 이의 제조 방법
EP1558214B1 (en) Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same
JPS6323964B2 (ja)
WO2002020037A1 (fr) Composition pharmaceutique a administration orale liberee au niveau colique
JPH08502288A (ja) 感昌症状を治療するための医薬組成物及び用法
JPS6160620A (ja) ピログルタミン酸エステル類を含有する医薬品組成物
JP2002535351A5 (ja)
HUE026644T2 (en) Mixture for transdermal administration of low and high molecular weight compounds
RU99114830A (ru) Терапевтические средства
AU2009202267A1 (en) Immunogenic Compositions
CA2169172A1 (en) Percutaneously absorbable preparation
JPH069381A (ja) イブプロフェン含有軟カプセル剤
JP6374558B2 (ja) 皮膚科障害または皮膚科疾患を処置するための新規製剤および方法
JPS61280435A (ja) サイクロスポリン類のリンパ指向性製剤
JP3496158B2 (ja) トラネキサム酸配合ゼラチンカプセル製剤
JP2008247822A (ja) 鎮痛用組成物
JP3132085B2 (ja) 脂肪乳剤
JP4690334B2 (ja) ビフェニルジメチルジカルボキシレート及びシリビンを含む経口用マイクロエマルション組成物
AU2001241730B2 (en) Emulsions as solid dosage forms for oral administration
JP3093040B2 (ja) 敗血症用脂肪乳剤
JPS60214730A (ja) 軟膏基剤